L
eflunomide is a new immunomodulating agent acting as a disease modifying drug in rheumatoid arthritis (RA). 1 2 It is a pro-drug, exerting its therapeutic effect through its major metabolite, A771726. 3 Although the exact mechanism by which leflunomide exerts its effect in RA is largely unknown, it appears to have several potential sites of action. A771726 inhibits dihydro-orotate reductase impeding de novo pyrimidine synthesis, resulting in decreased lymphocyte proliferation. 4 5 A771726 also interacts with primary and secondary signalling events by interference with the phosphorylation of tyrosine kinase. 6 7 In addition, A771726 may reduce the local concentration of inflammatory mediators by inhibiting the release of histamine from mast cells and of reactive oxygen species from white blood cells. 8 In vivo, leflunomide has been shown to directly affect synovial tissue, by decreasing expression of adhesion molecules and metalloproteinase-1. 9 However, other aspects of the direct effect of A771726 in synovial cells are not well known.
RA is characterised by synovial proliferation (pannus formation) and by local release of proinflammatory cytokines and metalloproteinases, leading to the destruction of cartilage and other articular components. 10 In all of them, the synovial mesenchymal cell has a central role, both as a proliferating cell as well as producer of proinflammatory cytokines and presenter of antigen to T cells. 11 In vitro studies of synovial fibroblast function and its modulation may be useful for the understanding of pharmacological agents in vivo. 12 We report herein the effects of A771726, the active metabolite of leflunomide, on the production of interleukin 1β (IL1β), tumour necrosis factor (TNFα), nitric oxide (NO), and stromelysin (metalloproteinase-3 (MMP-3)) in human synovial cells and synovial cultures.
MATERIALS AND METHODS
Specimen selection and culture conditions Synovial tissue was obtained during surgery from patients undergoing total knee replacement owing to RA (two female patients aged 58 and 64) or osteoarthritis (OA; two female patients aged 62 and 68).
Synovial cells derived from small pieces (2 mm in diameter) of human synovial tissue were grown after trypsinisation in monolayers in tissue culture flasks, by methods described by Castor et al. 13 Synovial cell lines were thus obtained and experiments performed in passages 2-4 after the first trypsinisation. The culture medium consisted of RPMI 1640, supplemented with L-glutamine (2 mM), penicillin (100 U/ml), and streptomycin sulphate (100 µg/ml) and 10% fetal calf serum (FCS NO was determined as previously described by Ashab et al.
14 NO 2 and NO 3 were determined after the reduction of NO 3 to NO 2 by 90 minutes' incubation in a tilting bath (37%) using nitrate reductase from Escherichia coli and β-nicotinamide adenine dinucleotide phosphate as cofactor. The presence of NO 2 was determined with the Griess reagent. Sensitivity of the procedure was 3 µmol/l.
MMP-3 (stromelysin) was measured by an ELISA (Chemicon International Inc, USA).
Cell viability and toxicity determination
Cell viability and toxicity in the presence of the active leflunomide metabolite (LEF) in the doses used in these experiments were determined in human synovial monolayer cultures by the tetrazolium salt XTT assay (Beit Haemek, Israel). 15 LEF was obtained from the Aventis Company.
Statistical analysis
In synovial cell cultures, absolute values of IL1β, TNFα, NO, and MMP-3 were expressed per well. Statistical significance was performed using the Student's t test.
RESULTS

IL1β production
The leflunomide active metabolite (LEF) significantly inhibited LPS (3 µg/ml) stimulated release of IL1β in the medium of human synovial tissue cultures in a dose dependent manner (p<0.01 at LEF 0.3 µg/ml) (fig 1) by 78%, 82%, and 85% at doses of 0.3 µg/ml, 3 µg/ml, and 9 µg/ml respectively.
TNFα production
The production of TNFα in the medium of IL1β (1 ng/ml) stimulated synovial tissue cultures was significantly inhibited by LEF in a dose dependent manner (p<0.05 at LEF 0.3 µg/ml) (fig 2) by 40%, 60%, and 90% at doses of 0.3 µg/ml, 1 µg/ml, and 3 µg/ml, respectively. NO and MMP-3 production NO release in the medium of LPS (3 µg/ml) stimulated cultures was inhibited by LEF in a dose dependent manner at LEF 3 µg/ml (p<0.01), while the inhibition achieved at a dose of 0.3 µg/ml was not significant (fig 3) .
Release of LPS stimulated MMP-3 was significantly inhibited by the different doses of LEF (p<0.01 at LEF 0.3 µg/ml, 1 µg/ml, 3 µg/ml, and 9 µg/ml) (fig 4) .
There was no qualitative difference in the response of RA and OA synovial cultures to LEF.
Cell viability and toxicity
Evaluation of toxicity to LEF in the concentrations used in these experiments as measured in human synovial cell cultures by the tetrazolium salt XTT assay showed no toxicity ( fig 5) .
DISCUSSION
In this study we have shown that A771726, the active metabolite of leflunomide, used in doses within the therapeutic range, 16 causes a dose dependent reduction of production of IL1β, TNFα, NO, and MMP-3 release in synovial tissue culture media. No qualitative difference in the response of RA and OA synovial cultures to LEF was found. This might be related to the selection of patients with RA, who where end stage patients requiring surgery, or to the cytokine profile studied.
Although the pathogenetic mechanism of RA remains elusive, great advances in molecular biology and clinical research have identified a complex orchestration of immune subset cells, cell surface markers, soluble cell products such as cytokines, and other inflammatory products. 17 Inflammation and subsequent degradation of the synovial tissue is probably induced by the influx of lymphocytes, triggered by an unknown antigen. In an oversimplified schema, activated T cells stimulate plasma cells, macrophages, and synovial fibroblasts to produce TNFα and IL1β, which are key agents in the process of inflammation. 18 LEF suppresses proliferation of lymphocytes and may thus modulate the inflammatory process by reducing the influx of immune cells to the synovia. 4 This may be the subcellular mechanism for the observed inhibition of TNFα, IL1β, and MMP-3, whereas inhibition of NO may be due to direct suppression of inducible nitric oxide synthase (iNOS) activation in fibroblasts by leflunomide through inhibition of the MEK/MAP pathway. 19 The reduced production of TNFα and IL1β by synovial fibroblasts shown in our study is in concordance with the observation of Kraan et al, who reported a reduced expression of TNFα and IL1β in synovial tissues of patients with RA treated with leflunomide as well as a decreased expression of adhesion molecules and MMP-1. 9 Metalloproteinases seem to have an important role in joint inflammation and in articular degeneration. 20 MMP-3 levels in serum and synovial fluid are increased in patients with active RA 21 and correlate with the degree of joint erosion, suggesting its involvement in joint inflammation and articular erosions. 22 The reduction of MMP-3 produced in synovial cells culture by A771726 may explain the disease modifying effect of leflunomide in patients with RA and the deceleration in joint erosions seen in clinical trials. 23 Our study shows that leflunomide produces a significant dose dependent suppression of NO production by synovial cells. Studies performed during the past years clearly indicate an important role for NO in inflammation. 24 Nitric oxide is a pleiotropic inflammatory mediator overproduced in joints affected by arthritis. iNOS is found in both the synovial tissue and cartilage and plays a part in the pathogenic process that occurs in the pannus of RA. 24 NO has been implicated in the development of both central 25 and peripheral pain. 26 27 It has been implicated as one of the important mediators of articular damage, in part through modulation of production of metalloproteinases by the rheumatoid cells 28 and apoptosis. 29 Several drugs, including non-steroidal anti-inflammatory drugs, 30 tetracyclines, 31 corticosteroids, 32 and immunosuppressive drugs such as cyclosporin A and mycophenolate mofetil, attenuate the activation of NO. 33 It has recently been shown that treatment of patients with RA with anti-TNFα monoclonal antibody significantly reduces iNOS type 2 protein expression and iNOS enzyme activity, the changes in iNOS activity correlating clearly with the degree of improvement in the number of tender joints. 34 Leflunomide's metabolite A771726 has been found to cause a dose dependent decrease of NO production in interferon gamma stimulated astrocytes 19 and fibroblasts. 35 Specific inhibition of MAP, PD 98058, but not unselective protein kinase inhibitor, completely mimicked the cell type specific and stimulus specific NO inhibitory action of leflunomide, suggesting that the suppression of iNOS activation in fibroblasts by leflunomide is through inhibition of the MEK/MAP pathway. 19 In conclusion, our study indicates that A771726, the active metabolite of leflunomide inhibits production of TNFα, IL1β, NO, and MMP-3 by human synovial cells, in vitro. Inhibition of TNFα, IL1β, NO, and MMP-3 is an important mechanism by which leflunomide may affect pain, articular inflammation, and joint damage. Further studies are needed to establish the in vivo significance of these findings. Rheumatologists are called to collaborate in treating childhood JIA P aediatric rheumatologists in two specialist centres in the UK are calling for international collaboration to refine a promising treatment for children with severe juvenile idiopathic arthritis (JIA) when other options have failed. The treatment is intense immunosuppression followed by autologous haemopoietic stem cell transplantation (ASCT), and future steps are understanding how it works in molecular terms and predicting who will benefit so that treatment can start before severe complications set in.
More than 45 children worldwide have had ASCT, and the signs are hopeful. In continental Europe results for 45 children, which are being written up, show about half in "complete" (drug free) remission, and in a published series 16 of 29 children were in drug free remission three years after treatment and eight were in partial remission or relapse, needing drug treatment.
ASCT carries with it appreciable risks of death and fatal complications. So selecting patients is crucial and is subject to consensus guidelines. Eligible children are those who show JIA, failed drug treatment, and drug toxicity; their disease must be controlled; and they must have no fevers or infections. Additionally, the family and the children are counselled carefully about risks and benefits against other treatments and about the lengthy, stressful, nature of the treatment and the uncertainty of the outcome. The psychological demands on patients and families are appreciable.
Two children in the UK have been treated so far, with good results. In true collaborative spirit the data will be added to the European Blood and Marrow Transplantation (EBMT) database. 
